Hematologic Malignancies and Stem Cell Transplantation Institute
Led by Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, our dedicated, multidisciplinary team combines innovative laboratory research discoveries to develop novel clinical treatments that will improve outcomes for patients.
The Mission of the Institute is to bring pioneering research discoveries in hematological malignancies and stem cell transplantation to early-phase clinical trials of potentially practice-changing therapies.
The Vision of the Institute is to become one of the foremost research and clinical treatment centers for hematological malignancies and stem cell transplantation, making the best available therapies accessible to all patients.
The institute is a matrix comprised of seven centers, each with a focus on a particular disease or treatment modality. Because the specific diseases can frequently be treated by multiple modalities, there is deliberate cross-pollination between the centers, with most faculty collaborating in research involving two or more centers.
GEHR FAMILY CENTER FOR LEUKEMIA RESEARCH
Led by Guido Marcucci, M.D., and Anthony Stein, M.D., the Gehr Family Center for Leukemia Research at City of Hope seeks to further expand and broaden our world-renowned work in the research and treatment of acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. The center focuses on discovering new actionable molecular targets, developing novel targeted therapies, and implementing these therapies in precision-medicine approaches.
JUDY AND BERNARD BRISKIN CENTER FOR MULTIPLE MYELOMA RESEARCH
The goal of the Judy and Bernard Briskin Center for Multiple Myeloma Research, directed by Amrita Krishnan, M.D., is to make multiple myeloma, and the related light chain amyloidosis, manageable non-lethal diseases. Center researchers are achieving this goal by aggressively pursuing and encouraging new research, developing improved treatments, and collaborating with myeloma and amyloid experts nationally and internationally.
TONI STEPHENSON LYMPHOMA CENTER
City of Hope has a long history of specializing in lymphoma, which includes some of the most common (Hodgkin, diffuse large B-cell, follicular and small lymphocytic lymphomas) and the rarest (T-cell non-Hodgkin, marginal and mantle cell lymhoma, Burkitt’s and hairy cell lymphomas) of hematological malignancies. Led by Larry Kwak, M.D., Ph.D. and and Robert Chen, M.D., the Toni Stephenson Lymphoma Center is committed to eliminating this disease by developing immune-based, non-transplant therapies, many of which have already shown promise in City of Hope’s laboratories.
CENTER FOR STEM CELL TRANSPLANTATION
The Center for Stem Cell Transplantation uses leading-edge research to advance hematopoietic stem cell transplant methods. Our dedicated team, directed by Ryotaro Nakamura, M.D. and David Snyder, M.D., is working to reduce treatment toxicity and improve patient outcomes. Our researchers have access to a large transplant patient population, rich historical data, and a clinical department with a reputation for outstanding transplant outcomes for 12 years running. Center research focuses on donor types, treatment complication such as graft-vs-host disease, cytomeglovirus vaccination, and regimens designed to reduce the risk of relapse.
CENTER FOR T CELL IMMUNOTHERAPY
City of Hope’s Center for T Cell Immunotherapy is finding new ways to harness the body’s immune system to fight cancer, using a patient’s own T lymphocytes from the blood. Led by Stephen Forman, M.D. and Christine Brown, Ph.D., researchers are discovering and applying new, T cell therapies by genetically reprogramming T cells with chimeric antigen receptors (CARs) to tailor the patient’s immune response to their specific cancer. CAR-T cell therapy has been making news recently and the Center for T Cell Immunotherapy is developing and clinically testing CAR-based treatments for leukemia, lymphoma, myeloma, and solid tumors (brain, breast, prostate, liver, and ovarian).
CENTER FOR GENE THERAPY
The Center for Gene Therapy, led by John Zaia, M.D., and Kevin Morris, Ph.D.,is world-class leader in research on stem-cell based therapies, and is dedicated to converting that research into real-world treatments and cures as rapidly as possible. The Center for Gene Therapy uses a patient’s own blood stem cells to introduce new genes or small non-coding RNAs that will combat and prevent cancer, HIV/AIDS, hemophilia and other deadly diseases. This highly specialized therapy is delivered in the City of Hope Alpha Clinic for Stem Cell Therapy.
CENTER FOR SURVIVORSHIP
Directed by Saro Armenian, D.O., M.P.H., the goal of the Center for Survivorship is to improve the overall quality of life for survivors of hematological (blood, bone marrow, lymph node) cancers. The Center for Survivorship provides specialized long-term follow-up care for patients of all ages, who have been treated with all modalities. This center seeks to facilitate evaluation of health outcomes in this previously understudied patient population. Using insights from this survivorship research, treatment plans for patients with blood cancers have been modified to reduce the long-term side effects of their cancer therapy.